Skip to main content

Biomarkers for cancer immunotherapy

This Biomarker Research thematic series includes research studies and reviews on biomarkers for diagnosis, prognosis, and targeted therapy for cancer immunotherapy, as well as novel and major advances in methodologies and materials for biomarker research. 

Biomarkers for cancer immunotherapy © © wildpixel / Getty Images / iStock

  1. Inflammation is a process that protects organs against various potentially harmful stimuli and enables repair. Dysregulated inflammation, however, damages tissues and leads to disease, including cancer. Cancer...

    Authors: Jun Zhang and Nirmal Veeramachaneni
    Citation: Biomarker Research 2022 10:5
  2. Cell therapy has evolved rapidly in the past several years with more than 250 clinical trials ongoing around the world. While more indications of cellular therapy with chimeric antigen receptor – engineered T ...

    Authors: Hongtao Liu, Chongxian Pan, Wenru Song, Delong Liu, Zihai Li and Lei Zheng
    Citation: Biomarker Research 2021 9:62
  3. Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have recently been characterized as attractive targets for cancer immunotherapy. Owing to the development of next-generatio...

    Authors: Xuan Zhao, Xiaoxin Pan, Yi Wang and Yi Zhang
    Citation: Biomarker Research 2021 9:61
  4. SMAD1, a central mediator in TGF-β signaling, is involved in a broad range of biological activities including cell growth, apoptosis, development and immune response, and is implicated in diverse type of malig...

    Authors: Jian Wu, Min Zhang, Omar Faruq, Eldad Zacksenhaus, Wenming Chen, Aijun Liu and Hong Chang
    Citation: Biomarker Research 2021 9:48
  5. miRNA-21 is among the most abundant and highly conserved microRNAs (miRNAs) recognized. It is expressed in essentially all cells where it performs vital regulatory roles in health and disease. It is also frequ...

    Authors: Ana E. Jenike and Marc K. Halushka
    Citation: Biomarker Research 2021 9:18
  6. A subset of men with metastatic prostate cancer (mPC) responds to immune checkpoint inhibitors, and there is an unmet need to predict those most likely to benefit. We characterized circulating tumor cells (CTC...

    Authors: Tian Zhang, Anika Agarwal, R. Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, Chandra Rao, Monika Anand, Taofik Oyekunle, Patrick Healy, Megan A. McNamara, Kathryn Ware, Jason A. Somarelli, Daniel J. George and Andrew J. Armstrong
    Citation: Biomarker Research 2021 9:14